Coave Therapeutics and Théa Open Innovation sign exclusive licensing, co-development and commercialization agreement for Europe for CTx-PDE6b, a novel gene therapy candidate in retinitis pigmentosa

Post by: Geert in Horama Press Release
Coave Therapeutics and Théa Open…
read more
16 Sep 2021
0

Coave Therapeutics Closes €33 million ($39 million) Series B Financing to Develop its Gene Therapy Pipeline and Next-Generation Vectors based on its AAV-Ligand Conjugate Platform

Post by: Geert in Horama Press Release
Coave Therapeutics Closes €33 million…
read more
22 Jul 2021
0

HORAMA appoints life sciences veteran Benedikt Timmerman as new Chairman

Post by: Geert in Horama Press Release
HORAMA appoints life sciences veteran…
read more
18 May 2020
0

HORAMA appoints industry veteran Ian Catchpole as Chief Scientific Officer

Post by: Geert in Horama Press Release
HORAMA appoints industry veteran Ian…
read more
04 May 2020
0

HORAMA Signs Exclusive License Agreement with Leiden University Medical Center Targeting CRB1 Gene Mutations to Treat Inherited Retinal Dystrophies

Post by: Geert in Horama Press Release
HORAMA Signs Exclusive License Agreement…
read more
19 Mar 2020
0

HORAMA strengthens its management team with the appointment of Rodolphe Clerval as Chief Business Officer (CBO)

Post by: Geert in Horama Press Release
HORAMA strengthens its management team…
read more
13 Mar 2020
0